Scientia CRO Sp. z o.o
Scientia CRO Sp. z o.o is recorded as a service provider in 12 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 12 of 12 trials · Latest update first
Optimization of the duration of treatment and dosing of vemurafenib in pediatric patients with histiocytic cell neoplasms refractory to conventional therapy and with a BRAF gene mutation
Sponsor Instytut Matki I Dziecka
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of Allopurinol on the Risk of Cardiovascular Events in Patients With High and Very High Cardiovascular Risk, Including the Presence of Long-COVID Syndrome.
Sponsor Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznaniu
- Start (EU)
- Latest update
- Estimated end
- Not reported
Assessment of the Molecular Profile and the Utility and Safety of Fludeoxyglucose (18F-FDG) PET/CT Imaging in Paediatric Patients With Histiocytic Neoplasms
Sponsor Instytut Matki I Dziecka
- Start (EU)
- Latest update
- Estimated end
- Not reported
Pulmonary Resistance Modification Under Treatment With Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction (PRESENT-HF Study)
Sponsor Uniwersytecki Szpital Kliniczny W Poznaniu
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available9 trial-level findings · Read insights
- The trial was conducted in Poland only.
- Protocol Version 4.0 reduced the minimum planned sample size from 230 to 32 participants.
- Protocol Version 4.0 modified the number of participating sites.
- Protocol Version 4.0 introduced telephone visits for selected outpatient visits.
- Protocol Version 4.0 permitted qualifying historical right-heart-catheterisation results for screening.
- A protocol amendment introduced washout of previous ACE inhibitor or ARB therapy before study treatment.
- Only 22 participants were included in the per-protocol population, and Month 12 paired haemodynamic data were available for 12 enalapril and 11 sacubitril/valsartan participants for mPAP and for 11 and 9 participants, respectively, for PVR.
- The low number of clinical events was insufficient for precise time-to-event inference, and those analyses were considered exploratory.
- Substantial variability, individual extreme values, and missing observations limited precision for several haemodynamic and secondary endpoint comparisons.
These findings describe the trial, not the service provider’s performance or responsibility.
LBL 2018 – International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma
Sponsor Universitaetsklinikum Muenster AöR
- Start (EU)
- Latest update
- Estimated end
Phase 2, randomized, blinded, non-treatment-controlled study assessing the efficacy and safety of dimethyl fumarate in patients with NBIA, a neurodegeneration associated with brain iron accumulation.
Sponsor Instytut Psychiatrii I Neurologii
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Optimalization Of The Time And Dosage Of Trametinib In BRAF Negative Juvenile Patients With Refractory Histiocytosis Or After Failure Of Vemurafenib Treatment.
Sponsor Instytut Matki I Dziecka
- Start (EU)
- Latest update
- Estimated end
- Not reported
A multicenter, prospective clinical TRrial evaluating patient’s ability to make an independent and safe decision regarding the USe of the medicinal product Sildenafil Polpharma100 mg indicated in the Treatment of erectile dysfunction. TRUST Trial on Responsible Use and Self-assessed Treatment.
Sponsor ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Non-commercial clinical trial of statins CAncer preventive and Pleiotropic TherApy IN smokers with chronic obstructive pulmonary disease (COPD) Clinical part: Atorvastatin effect on reduction of COPD exacerbations. Genomic part: Assessment of immunobiology of COPD related lung carcinoma and inflammatory pathways activation based on gene expression profiles of the peripheral blood leukocytes (PBLs) and peripheral blood mononuclear cells (PBMCs) from smokers with chronic obstructive pulmonary disease (COPD).
Sponsor Medical University Of Bialystok
- Start (EU)
- Latest update
- Estimated end
- Not reported
A multi-centre, four-arm, randomised, double-blind study assessing the dose equivalence of bevacizumab in first-line therapy for ovarian cancer
Sponsor Uniwersytet Medyczny W Lublinie
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Scientia CRO Sp. z o.o?
The 2026-10-09 snapshot links Scientia CRO Sp. z o.o to 12 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Safety reporting & pharmacovigilance, Statistical analysis, among 13 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Scientia CRO Sp. z o.o?
The most frequently recorded therapeutic areas are Haematological Malignancies, Cardiology, Genetic and Congenital Disorders, Infectious Disease. Recorded phases include Phase 2, Phase 3, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Scientia CRO Sp. z o.o conducted?
The linked trials record locations in 15 countries, including Poland, Austria, Czechia, Germany, Italy. These are trial locations, not confirmed office locations or countries where Scientia CRO Sp. z o.o delivered services.
What can this page tell me about Scientia CRO Sp. z o.o's trial experience?
Browse 12 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Scientia CRO Sp. z o.o. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Scientia CRO Sp. z o.o.